• Skylight Health Group (SLHG) has announced a non-brokered private placement for gross proceeds of up to $2 million
  • The company will issue up to 2,000 debenture units at $1,000 per unit
  • Each debenture will bear an annual interest rate of 8 per cent, paid quarterly in shares
  • The proceeds from the offering will be used for general working capital purposes
  • Skylight Health operates a U.S. multi-state primary care health network providing sub-specialty, allied health and laboratory/diagnostic testing
  • Skylight Health Group Inc. (SLHG) opened trading at $0.7369

Skylight Health Group (SLHG) has announced a non-brokered private placement for gross proceeds of up to $2 million.

The company will issue up to 2,000 debenture units at $1,000 per unit.

Each debenture will bear an annual interest rate of 8 per cent, paid quarterly in shares, and shall have a maturity date of February 15, 2025.

Each debenture shall be convertible into 1,111 common shares at C$0.90. Each debenture holder shall also receive 1,111 share purchase warrants. Each warrant entitles the holder to purchase one common share for a period 24 months.

The proceeds from the offering will be used for general working capital purposes.

The offering is expected to close on or about August 15, 2022.

Skylight Health operates a U.S. multi-state primary care health network providing sub-specialty, allied health and laboratory/diagnostic testing.

Skylight Health Group Inc. (SLHG) opened trading at $0.7369.


More From The Market Online
Man riding bull on a chart

Three micro-cap stocks on an upswing worth riding

It takes an encyclopedic drive to build a sense of the Canadian micro-cap stock universe and identify the highest probabilities for success.
Breath Collection Unit

Cannabix advances marijuana breathalyzer tech

Cannabix Technologies (CSE:BLO), announced significant updates to its Cannabix marijuana breathalyzer (CMB) technology.
CytoImmune Therapeutics production facility

Hemostemix stock takes off after amended manufacturing deal

Hemostemix (TSXV:HEM), a stem cell therapy stock, is up substantially after amending its manufacturing agreement with CytoImmune Therapeutics.